Description
Futibatinib
Each film-coated tablet contains: Futibatinib … 4mg.
INDICATION
LuciFutib is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
DOSAGE AND USE
• Confirm the presence of an FGFR2 gene fusion or other rearrangement prior to initiation of treatment with LuciFutib. • Recommended dose is 20 mg orally (five 4 mg tablets) once daily until disease progression or unacceptable toxicity occurs. • Swallow tablet whole, with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciFutib during Pregnancy and Lactation.
Reviews
There are no reviews yet.